• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从大肠杆菌包涵体中分离出的微型纤溶酶原和微纤溶酶原的复性、纯化及激活

Refolding, purification, and activation of miniplasminogen and microplasminogen isolated from E. coli inclusion bodies.

作者信息

Medynski Dan, Tuan Michael, Liu Wayne, Wu Shili, Lin Xinli

机构信息

Proteomtech Inc., 3505 Cadillac Ave., Building F7, Costa Mesa, CA 92626, USA.

出版信息

Protein Expr Purif. 2007 Apr;52(2):395-402. doi: 10.1016/j.pep.2006.10.012. Epub 2006 Oct 26.

DOI:10.1016/j.pep.2006.10.012
PMID:17126563
Abstract

Two des-kringle derivatives of human plasminogen, microplasminogen and miniplasminogen, have been expressed at high levels as inclusion bodies in Escherichia coli using a T7 expression system. In each case, the isolated inclusion bodies were refolded and purified. A final yield of approximately 10% of total refolded protein was observed in each case. Both refolded molecules were successfully activated to their functional forms, microplasmin and miniplasmin, by the plasminogen activator urokinase. The kinetic properties of the refolded microplasmin and miniplasmin were comparable to full length, native plasmin.

摘要

人纤溶酶原的两种去kringle结构域衍生物,微纤溶酶原和迷你纤溶酶原,已使用T7表达系统在大肠杆菌中作为包涵体高水平表达。在每种情况下,分离得到的包涵体都进行了复性和纯化。每种情况下都观察到最终产量约为复性总蛋白的10%。两种复性分子都被纤溶酶原激活剂尿激酶成功激活为其功能形式,即微纤溶酶和迷你纤溶酶。复性后的微纤溶酶和迷你纤溶酶的动力学特性与全长天然纤溶酶相当。

相似文献

1
Refolding, purification, and activation of miniplasminogen and microplasminogen isolated from E. coli inclusion bodies.从大肠杆菌包涵体中分离出的微型纤溶酶原和微纤溶酶原的复性、纯化及激活
Protein Expr Purif. 2007 Apr;52(2):395-402. doi: 10.1016/j.pep.2006.10.012. Epub 2006 Oct 26.
2
Expression and characterization of recombinant human micro-plasminogen.重组人微纤溶酶原的表达与鉴定
Biotechnol Lett. 2007 Apr;29(4):517-23. doi: 10.1007/s10529-006-9290-5. Epub 2007 Jan 6.
3
Recombinant gene expression and 1H NMR characteristics of the kringle (2 + 3) supermodule: spectroscopic/functional individuality of plasminogen kringle domains.kringle(2 + 3)超模块的重组基因表达及1H NMR特征:纤溶酶原kringle结构域的光谱/功能特性
Biochemistry. 1996 Feb 20;35(7):2357-64. doi: 10.1021/bi9520949.
4
Characterization and biological activities of recombinant human plasminogen kringle 1-3 produced in Escherichia coli.在大肠杆菌中产生的重组人纤溶酶原kringle 1-3的特性及生物学活性
Protein Expr Purif. 2004 Jul;36(1):1-10. doi: 10.1016/j.pep.2004.02.019.
5
Refolding and purification of recombinant human VEGF-121 expressed as inclusion bodies in Escherichia coli.在大肠杆菌中以包涵体形式表达的重组人血管内皮生长因子-121的复性与纯化。
Nan Fang Yi Ke Da Xue Xue Bao. 2006 Aug;26(8):1083-6.
6
Refolding, purification, and characterization of a loop deletion mutant of human Bcl-2 from bacterial inclusion bodies.从细菌包涵体中复性、纯化及鉴定人Bcl-2的环缺失突变体
Protein Expr Purif. 1999 Mar;15(2):162-70. doi: 10.1006/prep.1998.0996.
7
Soybean disease resistance protein RHG1-LRR domain expressed, purified and refolded from Escherichia coli inclusion bodies: preparation for a functional analysis.从大肠杆菌包涵体中表达、纯化和重折叠的大豆抗病蛋白RHG1-LRR结构域:功能分析的准备工作。
Protein Expr Purif. 2007 Jun;53(2):346-55. doi: 10.1016/j.pep.2006.12.017. Epub 2006 Dec 27.
8
Renaturation, purification and characterization of streptokinase expressed as inclusion body in recombinant E. coli.在重组大肠杆菌中以包涵体形式表达的链激酶的复性、纯化及特性鉴定
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jan 15;861(2):218-26. doi: 10.1016/j.jchromb.2007.10.008. Epub 2007 Oct 13.
9
Refolding and purification of Zymomonas mobilis levansucrase produced as inclusion bodies in fed-batch culture of recombinant Escherichia coli.在重组大肠杆菌补料分批培养中以包涵体形式产生的运动发酵单胞菌果聚糖蔗糖酶的复性与纯化
Protein Expr Purif. 2000 Apr;18(3):388-93. doi: 10.1006/prep.2000.1204.
10
Refolding and purification of recombinant human PDE7A expressed in Escherichia coli as inclusion bodies.以包涵体形式在大肠杆菌中表达的重组人磷酸二酯酶7A的复性与纯化。
Protein Expr Purif. 2002 Jun;25(1):138-48. doi: 10.1006/prep.2002.1620.

引用本文的文献

1
Selection of mutant µplasmin for amyloid-β cleavage in vivo.体内突变 µ 型纤溶酶原对淀粉样 β 肽的切割选择。
Sci Rep. 2020 Jul 21;10(1):12117. doi: 10.1038/s41598-020-69079-8.
2
Biochemical and structural analyses suggest that plasminogen activators coevolved with their cognate protein substrates and inhibitors.生化和结构分析表明,纤溶酶原激活物与其同源蛋白底物和抑制剂是共同进化的。
J Biol Chem. 2019 Mar 8;294(10):3794-3805. doi: 10.1074/jbc.RA118.005419. Epub 2019 Jan 16.
3
The evolution of recombinant thrombolytics: Current status and future directions.
重组溶栓剂的演变:现状与未来方向。
Bioengineered. 2017 Jul 4;8(4):331-358. doi: 10.1080/21655979.2016.1229718. Epub 2016 Oct 3.
4
High-level expression, purification, and enzymatic characterization of truncated human plasminogen (Lys531-Asn791) in the methylotrophic yeast Pichia pastoris.截短型人纤溶酶原(Lys531 - Asn791)在甲基营养型酵母毕赤酵母中的高水平表达、纯化及酶学特性分析
BMC Biotechnol. 2015 Jun 9;15:50. doi: 10.1186/s12896-015-0179-z.
5
Decoy plasminogen receptor containing a selective Kunitz-inhibitory domain.含选择性 Kunitz 抑制结构域的诱饵纤溶酶原受体。
Biochemistry. 2014 Jan 28;53(3):505-17. doi: 10.1021/bi401584b. Epub 2014 Jan 13.
6
Purification and characterization of mutant miniPlasmin for thrombolytic therapy.突变型 miniPlasmin 的纯化与表征及其在溶栓治疗中的应用。
Thromb J. 2013 Jan 30;11(1):2. doi: 10.1186/1477-9560-11-2.